Page 40 - Umer Raffat News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Eli Lilly and Company (LLY) Q1 2021 Earnings Call Transcript Motley Fool Transcribers © The Motley Fool Logo of jester cap with thought bubble. Eli Lilly and Company (NYSE: LLY) Popular Searches Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q1 2021 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to our host, Mr. Kevin Hern. Please go ahead.SPONSORED: 10 stocks we like better than Eli Lilly and Company When investing geniuses David and Tom ...

Operator Good morning. My name is Ashley, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Biogen's First Quarter Earnings Call and Financial Updates. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions] Thank you. I would now like to turn the conference over to Mr. Mike Hencke, Director, Investor Relations. Mr. Hencke, you may begin your conference. Mike Hencke -- Director of Investor Relations Good morning, and welcome to Biogen's...

Dive Brief: Pfizer and BioNTech on Thursday released new results from the large, international study that led to U.S. authorization of their coronavirus vaccine last year, showing the shot's protective effects appear to hold up for at least six months. The updated data comes from an analysis of 927 symptomatic COVID-19 cases that occurred in the study through March 13. Pfizer's vaccine remained 91.3% effective and offered near-complete protection against severe disease. Notably, there were no cases among hundreds of vaccinated participants in South Africa, where a variant that can weaken vacc...

Dive Brief: An experimental pill meant to combat the new coronavirus appears to be safe and at least somewhat effective at cutting down the time that patients test positive for SARS-CoV-2 infection, according to early data from its developers Merck & Co. and Ridgeback Biotherapeutics. The data come from a Phase 2 study that enrolled just over 200 people with confirmed, active SARS-CoV-2 infections who showed symptoms of coronavirus disease. Participants were given either a placebo or Merck and Ridgeback's pill, called molnupiravir, and then monitored. The companies reported Saturday that amon...

Operator Greetings and welcome to the Athenex, Inc. Fourth Quarter and Fiscal Year 2020 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Mr. Steve Rubis, Senior Director of Investor Relations for Athenex. Thank you. You may begin. Steven Rubis -- Senior Director, Investor Relations Good morning and thank you for joining our conference call. This morning, we published two press releases. The first announces that we received a complete response letter from the FDA for Oral Paclitaxel. The second ...